Ampella Mining Limited
FRA:MOR ISIN:DE0006632003
MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys's goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The Company currently has therapeutic and research alliances with the majority of the world's largest pharmaceutical companies including Bayer-Schering, Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 40 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford).
News
MorphoSys AG (MUC:MOR) Antibody Shows Ability to Inhibit Disease in an Established RA Model
MorphoSys AG (MUC:MOR) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its management will give company presentations at two investor conferences in November 2008.
MorphoSys AG (MUC:MOR) Full Year Profit Guidance Increased
MorphoSys AG (MUC:MOR) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first nine months' 2008 results on October 30, 2008 at 7:30 a.m. CET.
MorphoSys AG (MUC:MOR) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Shionogi & Co., Ltd., Osaka, Japan, has elected to extend its current license agreement covering the use of MorphoSys's HuCAL technology in drug discovery, for three additional years. Under the terms of the agreement, Shionogi will continue to have the right to use MorphoSys's proprietary antibody library HuCAL GOLD for research purposes at one of its research sites. MorphoSys will receive annual user fees from Shionogi for access to the HuCAL technology. Further financial details were not disclosed.
MorphoSys AG (MUC:MOR) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has exercised its first option to participate in the development of a therapeutic antibody program within its collaboration with Novartis. In a first, pre-development step, Novartis will fund the companies' joint efforts until the program reaches formal pre-clinical development. MorphoSys will recognize its share of the funding as additional revenues.
MorphoSys AG (MUC:MOR) MOR103 anti-GM-CSF Antibody Shows Subpicomolar Affinity for its Target Molecule
MorphoSys AG (MUC:MOR) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its management will give company presentations at five investor conferences in September 2008.
MorphoSys AG (PINKSHEETS:MPHSF) Revenues up 16 %, Operating Profit More Than Doubled
MorphoSys AG (PINKSHEETS:MPHSF) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first six months' 2008 results on July 29, 2008 at 7:30 a.m. CEST.
###
4,607 COMPANY PROFILE VIEWS
- Diese Seite wurde besucht: (letzten 7 Tagen: 27) (letzten 30 Tagen: 119) (seit Veröffentlichung: 4607)
